Holen Sie sich die Stockscreener-App
5.27
0.00%
0.00
Handel nachbörslich:
5.27
Trisalus Life Sciences Inc Aktie (TLSI) Neueste Nachrichten
TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trisalus Life Sciences at Canaccord Genuity: growth bets build By Investing.com - Investing.com Nigeria
Trisalus Life Sciences at Canaccord Genuity: growth bets build - Investing.com
TriSalus Life Sciences (TLSI) Advances 2.87% as Shares Hold Above $5.45 SupportETH Profile - dars.gov.et
TriSalus Life Sciences earnings missed by $0.01, revenue topped estimates - Investing.com Canada
TriSalus Life Sciences (TLSI) Stock Surges As Losses Deepen Behind Strong Margins - Sahm
Securities Fraud Investigation Into TriSalus Life Sciences Inc - The National Law Review
TriSalus Life Sciences, Inc. (TLSI) stock price, news, quote and history - Yahoo Finance UK
TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Meets Expectations - MarketBeat
TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Q2 Earnings Call Highlights - MarketBeat
Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ... - Yahoo Finance
Earnings call transcript: TriSalus tops Q2 revenue forecast, stock slips after hours - Investing.com
Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
TLSI: Q2 revenue rose to $11.4M, with expanded OBL reimbursement and strong growth outlook - TradingView
TriSalus Q2 2026 Earnings: Gross Margin Rises as Operating Loss Widens - TradingKey
TriSalus Life Sciences, Inc. 2026: Revenue $11.41M, EPS ($0.16) — 10-Q Summary - TradingView
TriSalus Life Sciences Reports Second Quarter 2026 Results - marketscreener.com
Inside TriSalus Life Sciences (NASDAQ: TLSI) Q2 2026 performance - Stock Titan
TriSalus Life Sciences, Inc. Maintains Revenue Guidance for the Full Year 2026 - marketscreener.com
TLSI: Q2 revenue up 1.7% to $11.4M, gross margin 88%, and 2026 guidance reaffirmed at $54–$57M - TradingView
Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Q2 2026 -- GF Value Sees 20% Upside - Yahoo Finance
TriSalus Life Sciences Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
TriSalus Life Sciences (TLSI) Stock Forum and Discussion - Moomoo
TriSalus Life Sciences (TLSI) to Post Earnings on Thursday - MarketBeat
TriSalus CEO and CFO to Join Canaccord Fireside Chat Aug. 12 - Stock Titan
TriSalus Life Sciences Inc (TLSI) Cash Flow - TradingKey
TriSalus Life Sciences Inc (TLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
TriSalus Life Sciences Inc (TLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TriSalus Life Sciences Inc (TLSI) Balance Sheet - TradingKey
First Light Asset Management LLC Invests $20.27 Million in TriSalus Life Sciences, Inc. $TLSI - MarketBeat
TriSalus Life Sciences Inc (TLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TLSI Q1 2026 Earnings: Strong EPS Surprise as Company Focuses on PipelineLong-Term Guidance - dars.gov.et
TriSalus Life Sciences Inc (TLSI) Income Statement - TradingKey
TLSI|TriSalus Life Sciences Inc|Price:4.360|Chg%:+0.040 - TradingKey
TriSalus Life Sciences (TLSI) Q1 2026 Earnings: EPS Surprises to the Upside as Stock SlipsEarnings Acceleration Picks - dars.gov.et
TLSI|TriSalus Life Sciences Inc|Price:4.220|Chg%:-0.050 - TradingKey
TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSI - TradingView
TriSalus Life Sciences Inc (TLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TriSalus Life Sciences Initiates PREDICTT Clinical Trial - Medical Product Outsourcing
Lobbying Update: $90,000 of TRISALUS LIFE SCIENCES lobbying was just disclosed - Quiver Quantitative
Press Release: TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call - Moomoo
TriSalus Life Sciences to host Q2FY26 financial results call - scanx.trade
TriSalus sets Aug. 6 webcast for second-quarter results - Stock Titan
TriSalus Life Sciences (TLSI) Edges Higher as Stock Tests Key Resistance LevelsLow Risk Entry Stocks - dars.gov.et
Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSI - TradingView
TriSalus Life Sciences, Inc. (TLSI) reports Q1 loss, lags revenue estimates - MSN
TLSIW SEC FilingsTriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
First Light Asset Management, Mathew Arens report 10.74% stake in TriSalus (TLSI) - Stock Titan
Form 4 TriSalus Life Sciences Inc For: 6 July By Investing.com - Investing.com Nigeria
TriSalus (TLSI) CFO has shares withheld to cover RSU tax obligations - Stock Titan
TriSalus Life Sciences, Inc. Warrant 2023-04.08.2028 on TriSalus Life Sciences Financial Disclosures & SEC Filings - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Scien - The National Law Review
TriSalus Life Sciences (TLSI) Stock Analysis Report | Financials & Insights - Benzinga
TriSalus (TLSI) CEO Mary Szela acquires 3,990 ESPP shares, now holds 1.08M - Stock Titan
TriSalus Life Sciences (TLSI) CCO acquires 561 ESPP shares - Stock Titan
Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSI - TradingView
Form 4 TriSalus Life Sciences Inc For: 29 June By Investing.com - Investing.com Canada
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):